Science AI Journal
Medicine · Research topic

Open research questions in Pharmacology and Obesity Treatment

99 unresolved questions extracted from the limitations and future-work sections of 464 Pharmacology and Obesity Treatment papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • Anti-obesity medications (AOMs) are recommended when target weight loss is not achieved; however, their efficacy among BT nonresponders has not been established.

    Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial · 2025 · DOI

  • Long-term assessment of the sustained efficacy and impact on reproductive outcomes, including the pattern of ovulation and offspring health, is warranted.

    Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS- A critical review of the evidence · 2025 · DOI

  • However, with all the positive outcomes, the major limitations using this drug for weight loss are the need for daily subcutaneous injections, cost, and gastrointestinal adverse effects.

    Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS- A critical review of the evidence · 2025 · DOI

  • The weight trajectory after discontinuation of short-term semaglutide treatment in obese women with PCOS who continued metformin treatment has not yet been evaluated.

    The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study · 2024 · DOI

  • However, the effects of these nitrates on cardiopulmonary performance in female athletes remain underexplored.

    Effect of Beetroot Juice Supplementation on Aerobic Capacity in Female Athletes: A Randomized Controlled Study · 2024 · DOI

  • 11) Evaluate the cognitive factors that are included in most programs by consensus, hut which have not been studied in detail.

    Improving long-term weight loss: Pushing the limits of treatment · 1987 · DOI

  • There is not enough clinical evidence to make traditional Chinese medicine widely used. Weight gain again after surgery and the need to closely check for related problems are still challenges.

    Current Status of Weight Loss Therapy in Achieving Remission of Type 2 Diabetes Mellitus · 2026 · DOI

  • Obesity is a chronic disease with increasing prevalence and substantial health consequences. Current treatments have limitations, and new pharmacological options are needed. Maintaining weight loss remains a key challenge in obesity management.

    Efficacy and Safety of Tirzepatide in the Treatment of Obesity: A Review of Current Clinical Trials · 2026 · DOI

  • There is a need for effective pharmacological options for the treatment of obesity. Current treatments have limitations, and new options are needed. The paper identifies a gap in the literature regarding the long-term safety and efficacy of tirzepatide.

    Efficacy and Safety of Tirzepatide in the Treatment of Obesity: A Review of Current Clinical Trials · 2026 · DOI

  • Further investigation of the potential PL inhibitors identified in this study - Exploration of other Traditional Chinese medicines as potential PL inhibitors - Investigation of the inhibitory activity of the compounds in vivo

    Identification of Potential Pancreatic Lipase Inhibitors from Traditional Chinese Medicines via Molecular Docking, Molecular Dynamics Simulation and In Vitro Validation · 2026 · DOI

  • Clinical synthetic PL inhibitors are greatly restricted by adverse reactions. There is a need to develop safe and efficient PL inhibitors. TCM components may be a promising source for developing PL inhibitors, but their inhibitory activity needs to be investigated.

    Identification of Potential Pancreatic Lipase Inhibitors from Traditional Chinese Medicines via Molecular Docking, Molecular Dynamics Simulation and In Vitro Validation · 2026 · DOI

  • The development of effective therapeutic approaches for obesity is a significant challenge. The implementation of public health policies to reduce the availability of highly processed foods and promote physical activity is a challenge. The need for a comprehensive approach, considering lifestyle and environmental factors, is a challenge.

    Current diagnostic and therapeutic approaches in obesity management · 2026 · DOI

  • The current approach to obesity management is often inadequate, focusing solely on individual factors. There is a need for a comprehensive approach, considering lifestyle and environmental factors.

    Current diagnostic and therapeutic approaches in obesity management · 2026 · DOI

  • Future updates may incorporate evolving standards in the definition and management of obesity, broader patient populations and geographic settings, new pharmacotherapies and formulations, and additional clinically relevant endpoints as the evidence base develops.

    Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO): 2026 update · 2026 · DOI

  • The evidence base for several complication domains remains sparse or heterogeneous. Several clinically important outcomes are not yet represented as distinct domains in the algorithm.

    Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO): 2026 update · 2026 · DOI

  • The mechanisms underlying the effects of RYGB on metabolic regulation are not fully understood. The role of CELA2A in gastrointestinal metabolic signaling is not well characterized.

    Opposing gastric and jejunal regulation of CELA2A in obesity and after Roux-en-Y gastric bypass suggests a role in gastrointestinal metabolic signaling · 2026 · DOI

  • The study notes the challenges of treating obesity, including the need for effective pharmacological therapies and the limitations of access to these therapies. The study notes the challenges of individualizing treatment and considering comorbidities.

    Eficácia clínica e efeitos metabólicos dos agonistas de GLP-1 e GIP no tratamento da obesidade: uma revisão integrativa · 2026 · DOI

  • The study has limitations, including the potential for bias in the selected articles and the need for continuous use of the medications to maintain results. The study also notes the importance of individualizing treatment, considering comorbidities and the need for continuous treatment.

    Eficácia clínica e efeitos metabólicos dos agonistas de GLP-1 e GIP no tratamento da obesidade: uma revisão integrativa · 2026 · DOI

  • Obesity and excessive adiposity have a growing prevalence worldwide, constituting important challenges for public health. The disease hepática esteatótica associada à disfunção metabólica (MASLD) represents the most common form of chronic liver disease worldwide. There is a need to understand the impacts of tirzepatide use in the management of obesity-associated hepatic steatosis.

    Efeitos da Tirzepatida na Doença Hepática Esteatótica associada à disfunção metabólica em pacientes com obesidade: uma revisão integrativa · 2026 · DOI

  • There is a need to understand the impacts of tirzepatide use in the management of obesity-associated hepatic steatosis. The available scientific evidence on the effects of tirzepatide on metabolic dysfunction-associated steatotic liver disease in patients with obesity needs to be analyzed.

    Efeitos da Tirzepatida na Doença Hepática Esteatótica associada à disfunção metabólica em pacientes com obesidade: uma revisão integrativa · 2026 · DOI

  • The economic consequences of obesity on individuals, particularly in settings with limited public coverage for treatment, are not well understood. The study aims to address this gap by evaluating the out-of-pocket health expenditure associated with obesity.

    Out-of-pocket health expenditure among individuals with obesity · 2026 · DOI

  • The complex relationship between obesity and cognitive impairment. The limited number of RCTs and observational studies on the use of anti-obesity medications and cognitive disorder risk. The difficulty in detecting slowly progressive cognitive disorders.

    Anti-obesity medications and cognitive disorder risk: a discrepancy between RCTs and real-world evidence · 2026 · DOI

  • The included RCTs were primarily designed and powered to assess cardiovascular and metabolic outcomes, with cognitive disorders documented only as adverse events. The median 110-week follow-up in these trials was too short to detect slowly progressive cognitive disorders. The study had a limited number of RCTs and observational studies, which may affect the generalizability of the results.

    Anti-obesity medications and cognitive disorder risk: a discrepancy between RCTs and real-world evidence · 2026 · DOI

  • The mechanisms by which exercise and GLP-1 RAs ameliorate cardiovascular risk after weight loss remain to be determined. There is a need to investigate the effects of exercise and liraglutide on vascular health and inflammation during weight loss maintenance.

    Effects of exercise and liraglutide on vascular health and inflammation during weight loss maintenance: a prespecified secondary analysis of the S-LiTE trial · 2026 · DOI

  • Efficiency limitations and resource waste remain significant concerns in traditional Chinese medicine - The clinical efficacy of probiotic-fermented herbal residues requires further evaluation

    Probiotic-fermented herbal residues in obesity management: a review · 2026 · DOI

Most-cited papers in Pharmacology and Obesity Treatment

Most recent work

Find a gap in your own Pharmacology and Obesity Treatment sub-topic

This page shows what the Pharmacology and Obesity Treatment literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
2,044 open questions
Substance Abuse Treatment and Outcomes
1,964 open questions
Smoking Behavior and Cessation
990 open questions
Dementia and Cognitive Impairment Research
974 open questions
Innovations in Medical Education
960 open questions
Physical Activity and Health
923 open questions
Attention Deficit Hyperactivity Disorder
839 open questions
Schizophrenia research and treatment
709 open questions
99 open questions have been extracted from the limitations and future-work passages of 464 Pharmacology and Obesity Treatment papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.